240 related articles for article (PubMed ID: 30762670)
1. Salvage therapeutic strategies for bacillus Calmette-Guerin failure.
Hassler MR; Shariat SF; Soria F
Curr Opin Urol; 2019 May; 29(3):239-246. PubMed ID: 30762670
[TBL] [Abstract][Full Text] [Related]
2. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
Turker P; Turkeri L
Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
[TBL] [Abstract][Full Text] [Related]
3. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
4. The Timing of Radical Cystectomy for bacillus Calmette-Guérin Failure: Comparison of Outcomes and Risk Factors for Prognosis.
Haas CR; Barlow LJ; Badalato GM; DeCastro GJ; Benson MC; McKiernan JM
J Urol; 2016 Jun; 195(6):1704-9. PubMed ID: 26807928
[TBL] [Abstract][Full Text] [Related]
5. Combination Intravesical Therapy.
Brooks NA; O'Donnell MA
Urol Clin North Am; 2020 Feb; 47(1):83-91. PubMed ID: 31757303
[TBL] [Abstract][Full Text] [Related]
6. Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.
Yates DR; Brausi MA; Catto JW; Dalbagni G; Rouprêt M; Shariat SF; Sylvester RJ; Witjes JA; Zlotta AR; Palou-Redorta J
Eur Urol; 2012 Dec; 62(6):1088-96. PubMed ID: 22959049
[TBL] [Abstract][Full Text] [Related]
7. Failure of Bacillus Calmette-Guérin therapy in non-muscle-invasive bladder cancer: Definition and treatment options.
Gual Frau J; Palou J; Rodríguez O; Parada R; Breda A; Villavicencio H
Arch Esp Urol; 2016 Sep; 69(7):423-33. PubMed ID: 27617552
[TBL] [Abstract][Full Text] [Related]
8. Salvage Therapy Using Bacillus Calmette-Guérin Derivatives or Single Agent Chemotherapy.
Haas CR; McKiernan JM
Urol Clin North Am; 2020 Feb; 47(1):47-54. PubMed ID: 31757299
[TBL] [Abstract][Full Text] [Related]
9. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
10. Identification of Candidates for Salvage Therapy: The Past, Present, and Future of Defining Bacillus Calmette-Guérin Failure.
Becker REN; Kates MR; Bivalacqua TJ
Urol Clin North Am; 2020 Feb; 47(1):15-21. PubMed ID: 31757296
[TBL] [Abstract][Full Text] [Related]
11. The current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer.
Packiam VT; Richards J; Schmautz M; Heidenreich A; Boorjian SA
Curr Opin Urol; 2021 May; 31(3):178-187. PubMed ID: 33742981
[TBL] [Abstract][Full Text] [Related]
12. Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer.
Smaldone MC; Gayed BA; Tomaszewski JJ; Gingrich JR
Minerva Urol Nefrol; 2009 Jun; 61(2):71-89. PubMed ID: 19451890
[TBL] [Abstract][Full Text] [Related]
13. Novel treatments in BCG failure. Where do we stand today?
Fragkoulis C; Glykas I; Bamias A; Stathouros G; Papadopoulos G; Ntoumas K
Arch Esp Urol; 2021 Sep; 74(7):681-691. PubMed ID: 34472437
[TBL] [Abstract][Full Text] [Related]
14. Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non-Muscle-Invasive Bladder Cancer.
McElree IM; Packiam VT; Steinberg RL; Mott SL; Gellhaus PT; Nepple KG; O'Donnell MA
J Urol; 2022 Nov; 208(5):969-977. PubMed ID: 35830552
[TBL] [Abstract][Full Text] [Related]
15. Intravesical and alternative bladder-preservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin.
Steinberg RL; Thomas LJ; Nepple KG
Urol Oncol; 2016 Jun; 34(6):279-89. PubMed ID: 26777259
[TBL] [Abstract][Full Text] [Related]
16. Long-term Survival Outcomes With Intravesical Nanoparticle Albumin-bound Paclitaxel for Recurrent Non-muscle-invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy.
Robins DJ; Sui W; Matulay JT; Ghandour R; Anderson CB; DeCastro GJ; McKiernan JM
Urology; 2017 May; 103():149-153. PubMed ID: 28163086
[TBL] [Abstract][Full Text] [Related]
17. Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC).
Álvarez-Maestro M; Guerrero-Ramos F; Rodríguez-Faba O; Domínguez-Escrig JL; Fernández-Gómez JM
Actas Urol Esp (Engl Ed); 2021 Mar; 45(2):93-102. PubMed ID: 33012593
[TBL] [Abstract][Full Text] [Related]
18. Non-muscle-invasive bladder cancer: Intravesical treatments beyond Bacille Calmette-Guérin.
Packiam VT; Johnson SC; Steinberg GD
Cancer; 2017 Feb; 123(3):390-400. PubMed ID: 28112819
[TBL] [Abstract][Full Text] [Related]
19. Second-line intravesical therapy versus cystectomy for bacille Calmette-Guérin (BCG) failures.
Joudi FN; O'Donnell MA
Curr Opin Urol; 2004 Sep; 14(5):271-5. PubMed ID: 15300147
[TBL] [Abstract][Full Text] [Related]
20. Bacillus Calmette-Guérin Salvage Therapy: Definitions and Context.
Konety BR; Narayan VM; Dinney CPN
Urol Clin North Am; 2020 Feb; 47(1):1-4. PubMed ID: 31757292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]